IP Library Granted Patent US 7,557,105
Granted Patent B2
US 7,557,105 · App. 10/502,291 · Granted Jul 7, 2009

N-oxides of N-phenyl-2-pyrimidine-amine derivatives

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,557,105
App. No.
10/502,291
Granted
Jul 7, 2009
Kind
B2
Abstract

The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

Claims (12)

1. A compound of formula I

wherein

R 1 is hydrogen or hydroxy,

R 2 is hydrogen, lower alkyl or hydroxy-lower alkyl,

A is a piperazinyl group of the formula A′

substituted by oxo on a ring carbon, and

R 3 is hydrogen, lower alkyl or acetyl,

in purified form or a pharmaceutically acceptable salt of such a compound.

2. A compound selected from the group consisting of 4-[(3-oxo-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide and 4-[(4-methyl-3-oxo-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide or a pharmaceutically acceptable salt thereof.

3. A compound which is 4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide or a pharmaceutically acceptable salt thereof.

4. A compound which is 4-[(4-methyl-1,4-dioxido-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2009
From: BORNSEN, KLAUS OLAF; END, PETER; GROSS, GERHARD; PFAAR, ULRIKA; MANLEY, PAUL WILLIAM; ZIMMERMANN SIGNED TWICE, JURG; ZIMMERMANN, JURG
To: NOVARTIS AG
Reel/Frame 022778/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2006
From: XIE, AMANDA QING
To: LUCENT TECHNOLOGIES INC.
Reel/Frame 018179/0168 →
Priority Claims (1)
GB 0201508.9 · Jan 23, 2002 · national
Continuity (1)
Related Publication 20050209452A1 · Sep 22, 2005